Featured Articles

  1. How Pharma Go-To-Market Strategy And Launch Readiness Are Transforming 4/7/2026

    Speed to market won't guarantee success in today's launch environment. Anticipating what prescribers, patients and payers will value is key, according to experts at EY.

  2. Does Biotech Need More Government Funding — Or A New Business Model? 3/30/2026

    Should government financing appreciably recede – whether through policy shifts, budget pressures, or ideological bent – what would happen to the biotech business model? To ascertain such a question, first we must look at the fundamentals of the existing model, and then understand investors (and service providers) better.

  3. The Silent Strategist: AI's "Hidden" Nudges Reshape Pipeline Strategy 3/26/2026

    With the wrong architecture in place, AI algorithms can 'nudge' biopharmaceutical developers toward unpredicted and misaligned results, according to experts.

  4. What If The U.S. Government Stopped Funding Biotech? 3/23/2026

    It sets off a real tension – ideological, economic, even personal. But what would happen if the U.S. government cut direct financial support for “biotechnology research,” leaving it entirely to investors, private and public markets, and bigger pharma? "Our industry’s mind-meld says with no government largesse our biotech industry collapses," writes Chief Editor Louis Garguilo. It's an "outlandish hypothetical," but he asks for a few minutes to go through this. And he has help in making his case.

  5. The Human Variable: The Leadership Risk Biotech Governance Still Ignores 3/12/2026

    The mental faculties a biotech CEO needs most are the first to degrade under chronic pressure. This is not a character issue, it's physiological, writes Maria Bostock.

  6. Building Strategic Partnerships Between IP Law Firms And Biopharma 3/4/2026

    Patent attorney Eric M. Brusca, Ph.D., explains how biopharmaceutical companies and their IP law firms can cultivate relationships that drive meaningful business value.

  7. Where Are They Now? Life Science Cares 2/27/2026

    Life Science Cares, an industry philanthropic organization, turns 10 in April. Now in five cities and Switzerland, the organization remains focused on fighting poverty.

  8. Life Sciences Hubs Creating More Opportunity For Startups And Investors 2/26/2026

    Life sciences hubs beyond Boston and the Bay Area are giving startups new opportunities to grow and scale their businesses, writes Mike Carnes at NCBiotech.

  9. How Strategic Collaborations Can Accelerate Innovation And Create Value 2/24/2026

    Platform biotechs should aim for partnerships that compound value over time, beyond a simple funding mechanism, writes Unnatural Products CEO Cameron Pye, Ph.D.  

  10. Time Is Lives: How Collaboration And Urgency Are Rewriting The Future Of Rare Disease 2/19/2026

    The inflection point has arrived, says Rob Freishtat, MD, MPH. Understand how collaboration will rewrite how we think of rare disease clinical research.